Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: May 28, 2025
Event: Discontinuation of worldwide sales for the ACURATE neo2 and ACURATE Prime Aortic Valve Systems and cessation of pursuit for U.S. FDA approval for the ACURATE platform.
Key Financial Metrics
This filing does not contain specific financial statements, revenue figures, profit margins, cash flow data, or debt levels. The document focuses on a strategic operational decision and its anticipated impact on guidance.
Material Changes and Strategic Decisions
- Product Discontinuation: The Company is stopping global sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems.
- Regulatory Withdrawal: The Company is no longer seeking U.S. FDA approval for ACURATE or approvals in other geographies.
- Rationale: Recent discussions with regulators resulted in increased clinical and regulatory requirements. The Company determined that the resources and investments required to satisfy these requirements are prohibitive.
Guidance, Outlook, and Risks
Management Commentary and Guidance
- Reaffirmed Guidance: The Company expects to achieve its second quarter and full year 2025 reported and organic sales and adjusted earnings per share (EPS) guidance issued on April 23, 2025, despite anticipated financial impacts from the discontinuation.
- Withheld Guidance: The Company is not reaffirming its second quarter and full year 2025 GAAP EPS guidance at this time. Further details are expected during the second quarter 2025 earnings call.
Risks and Contingencies
- Financial Impact: Anticipated negative financial impacts from the discontinuation of the ACURATE valve platform.
- Operational Risks: Risks include the ability to manage the transition, regulatory changes, reimbursement conditions, supply chain disruptions, and litigation.
- Forward-Looking Statements: Actual results may differ materially from expectations due to incorrect assumptions or materialization of risks.
Investor Verification Checklist
- Verify the specific financial impact of the ACURATE discontinuation on GAAP EPS during the upcoming Q2 2025 earnings call.
- Confirm the timeline for the complete cessation of sales and the handling of existing inventory or patient follow-up.
- Review the Company's most recent Form 10-K for detailed risk factors regarding regulatory approvals and product lifecycle management.
- Monitor future filings for updates on the integration of cost-savings initiatives related to this decision.